.png)
Product Snapshot: SynvIchor by OrthoDx
- Terry Cornick
- May 8, 2020
- 1 min read
Welcome to the next post in our series of Product Snapshots in the Australian healthtech sector.
Say hello to SynvIchor by OrthoDx.
In one sentence, describe your product?
Personalised molecular genomic diagnostic for joint infections in Orthopaedic patients.
What industry problem / challenge are you tackling?
The infection of both native and prosthetic joints.
What is unique about your product in your market?
It is the only genomic diagnostic that differentiates infection from inflammation.
What is the biggest risk to your company?
Lack of understanding of how genomic diagnostics report probability instead of severity of disease.
What does success look like for the company?
Widespread adoption of this novel technology and a large improvement in patient outcomes such as reduced morbidity and mortality.
Why should a customer use SynvIchor? It is the most accurate orthopaedic infection diagnostic developed.
How do we find out about SynvIchor?
Sign up for our no-nonsense Doctology Download newsletter at the bottom of this page.
Comments